Vistagen Therapeutics, Inc. (VTGN)
About Vistagen Therapeutics, Inc.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2023
- -$227.0K
- Net income
- -$51.4M
- Total assets
- $84.3M
- Market cap
- $9.3M
- Operating margin
- -5683.7%
- Net margin
- -5491.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.3M
- Operating expenses
- $73.4M
- Operating income
- -$72.1M
- Income tax
- $7.0K
- Net income
- -$69.7M
- EPS (basic)
- $-1.83
- EPS (diluted)
- $-1.83
Balance sheet
- Total assets
- $48.6M
- Current assets
- $46.9M
- Total liabilities
- $13.0M
- Current liabilities
- $12.8M
- Shareholders’ equity
- $35.5M
Cash flow
- Operating cash flow
- -$66.4M
- Investing cash flow
- -$877.0K
- Financing cash flow
- $31.0M
- Net cash flow
- -$36.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $9.3M
- EPS (diluted)
- $-1.83
- Shares outstanding
- 35.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 1, 2009
Vistagen Therapeutics, Inc. (VTGN) Stock Price
- Reported a net loss of $51.4M in FY2023.
- Revenue grew 14% from FY2022 to FY2026.
- Trading 95% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Vistagen Therapeutics, Inc..
Write a review
News about Vistagen Therapeutics, Inc.
News & sentiment via Polygon.io
Vistagen Therapeutics, Inc.: frequently asked questions
Is Vistagen Therapeutics, Inc. an American company?
Vistagen Therapeutics, Inc. is a US-based company headquartered in South San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Vistagen Therapeutics, Inc. headquartered?
Vistagen Therapeutics, Inc. is headquartered in South San Francisco, California, United States.
Is Vistagen Therapeutics, Inc. publicly traded?
Yes — Vistagen Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol VTGN on the NASDAQ.
What does Vistagen Therapeutics, Inc. do?
Vistagen Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
